David Gerber

Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas. He discussed the evolving role of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).

Best podcasts with David Gerber

Ranked by the Snipd community

Jan 28, 2025 • 27min

S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD

In this insightful discussion, Dr. David Gerber, a professor at the University of Texas Southwestern Medical Center and expert in hematology/oncology, explores the transformative role of antibody-drug conjugates (ADCs) in treating non–small cell lung cancer (NSCLC). He highlights key findings from pivotal clinical trials, revealing the promising effectiveness of ADCs like datopotamab deruxtecan and patritumab deruxtecan. Dr. Gerber also addresses crucial issues on toxicity management and treatment sequencing, offering a glimpse into the future of targeted lung cancer therapies.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app